A Randomized, 9-Way, Single-Dose, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of LY3185643 and rGlucagon in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Glucagon (Primary) ; LY 3185643 (Primary)
- Indications Hypoglycaemia
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Eli Lilly
- 08 Mar 2017 Status changed from active, no longer recruiting to completed.
- 30 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.